Neoadjuvant bevacizumab (B) and trastuzumab (T) in combination with weekly paclitaxel (P) as neoadjuvant treatment in HER2-positive breast cancer: Results from a phase II trial (AVANTHER)

被引：0
|
作者：
Fernandez Abad, Maria
Calvo, Isabel
Martinez, Noelia
Herrero, Mercedes
Quijano, Yolanda
Duran, Hipolito
Garcia Aranda, Mariola
Suarez, Ana
Lopez-Rios, Fernando
Perez, Diego
Perea, Sofia
Hidalgo, Manuel
Garca-Estevez, Laura
机构：
[1] Ctr Integral Oncol Clara Campal, Madrid, Spain
[2] Hosp Ramon & Cajal, E-28034 Madrid, Spain
[3] Hosp Costa Sol, Marbella, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
602
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study
    Wang, Haoqi
    Li, Yuntao
    Qi, Yixin
    Zhao, Erbao
    Kong, Xiangshun
    Yang, Chao
    Yang, Qiqi
    Zhang, Chengyuan
    Liu, Yueping
    Song, Zhenchuan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [42] Translational Results of Zo-NAnTax: A Phase II Trial of Neoadjuvant Zoledronic Acid in HER2-Positive Breast Cancer
    Crocamo, Susanne
    Binato, Renata
    dos Santos, Everton Cruz
    de Paula, Bruno
    Abdelhay, Eliana
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (24)
  • [43] A PHASE II STUDY OF NEOADJUVANT WEEKLY PACLITAXEL WITH AND WITHOUT TRASTUZUMAB IN ELDERLY BREAST CANCER PATIENTS
    Sasaki, Y.
    Shimizu, C.
    Koudaira, M.
    Yunokawa, M.
    Yamamoto, H.
    Yonemori, K.
    Tamura, K.
    Fujiwara, Y.
    Ando, M.
    ANNALS OF ONCOLOGY, 2013, 24
  • [44] Efficacy and tolerability of neoadjuvant Pertuzumab, Trastuzumab, and weekly Paclitaxel in Locally advanced Her-2 positive Breast cancer
    Gupta, Niraj
    Giblin, Erica
    Spivey, Tara
    Govert, Kristen
    Leagre, Christopher
    Liebross, Robert
    Tumati, Vasu
    Dugan, Thomas
    Yadav, Rina
    Henman, Patrick
    Beaudrie, Nick
    Bair, Tessa
    Durk, Jessica
    Hancock, Marjaorie
    Engle, Trisha
    Myers, Michelle
    Schneiders, Julie
    Tigges, Thomas
    CANCER RESEARCH, 2021, 81 (04)
  • [45] De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab in HER2-positive early breast cancer (HELEN-006):a randomized,phase 3 trial
    Liu, Zhenzhen
    Chen, Xiuchun
    Qiao, Jianghua
    Jiao Dechuang
    Wang, Chengzheng
    Sun, Xianfu
    Lu, Zhenduo
    Li, Lianfang
    Zhang, Chongjian
    Yan, Min
    Wei, Ya
    Bo, Chen
    Feng, Yueqing
    Deng, Miao
    Ma, Mingde
    CANCER RESEARCH, 2024, 84 (09)
  • [46] Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer
    Baselga, J.
    Manikhas, A.
    Cortes, J.
    Llombart, A.
    Roman, L.
    Semiglazov, V. F.
    Byakhov, M.
    Lokanatha, D.
    Forenza, S.
    Goldfarb, R. H.
    Matera, J.
    Azarnia, N.
    Hudis, C. A.
    Rozencweig, M.
    ANNALS OF ONCOLOGY, 2014, 25 (03) : 592 - 598
  • [47] Phase II open clinical trial to evaluate efficacy and safety of neoadjuvant trastuzumab in HER2-positive locally advanced breast cancer (LABC)
    Arce-Salinas, C. H.
    Lara, F. U.
    Leon, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] Neoadjuvant ixabepilone/carboplatin/trastuzumab in HER2-positive locally advanced breast cancer: A Sarah Cannon Research Institute phase II trial
    Zubkus, J. D.
    Daniel, D. B.
    Eakle, J. F.
    Bechhold, R. G.
    Shastry, M.
    Tucker, P. S.
    Burris, H. A.
    Hainsworth, J. D.
    Yardley, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [49] Neoadjuvant trastuzumab in HER2-positive breast cancer, is pathological complete response enough?
    Ruvalcaba-Limon, Eva
    Pozo-Romero, Mariela
    Bautista-Pina, Veronica
    Tenorio-Torres, Alberto
    Morales-Vazquez, Flavia
    Rodriguez-Cuevas, Sergio
    ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : 342 - 344
  • [50] Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer
    Isabel Echavarria
    Mónica Granja
    Coralia Bueno
    Sara Lopez-Tarruella
    Paloma Peinado
    Miguel Sotelo
    Yolanda Jerez
    Fernando Moreno
    Gabriela Torres
    Miriam Lobo
    Ivan Marquez-Rodas
    Maria Del Monte-Millan
    Miguel Martín
    Jose Angel García-Saenz
    Breast Cancer Research and Treatment, 2017, 162 : 181 - 189
12345